 evidence to date
that combination therapy is a more effective treatment for
PAD than a single agent, and bleeding risks are increased.84
Warfarin has been demonstrated to reduce myocardial
infarction or stroke in patients with coronary artery disease,
although at the cost of a 4.5-fold increase in major
bleeding.85,86 There is no evidence that warfarin decreases
the likelihood of adverse events related to PAD alone. Only
one prospective trial